Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection

Ingrid Karlsson, Lea Brandt, Lasse Vinner, Ingrid Kromann, Lars Vibe Andreasen, Peter Andersen, Jan Gerstoft, Gitte Kronborg, Anders Fomsgaard

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

We investigated the potential of inducing additional T-cell immunity during chronic HIV-1 infection directed to subdominant HIV-1 epitopes from common HLA-supertypes. Ten treatment-naïve HIV-1-infected individuals were immunized with peptides in the adjuvant CAF01. One individual received placebo. T-cell immunogenicity was examined longitudinally by a flow cytometry (CD107a, IFNγ, TNFα, IL-2 and/or MIP1β expression) as well as IFNγ ELISPOT. Safety was evaluated by clinical follow up combined with monitoring of biochemistry, hematology, CD4 T-cell counts and viral load. New CD4 and CD8 T-cell responses specific for one or more vaccine epitopes were induced in 10/10 vaccinees. The responses were dominated by CD107a and MIP1β expression. There were no significant changes in HIV-1 viral load or CD4 T-cell counts. Our study demonstrates that the peptide/CAF01 vaccine is safe and that it is possible to generate new HIV-1 T-cell responses to defined epitopes in treatment-naïve HIV-1-infected individuals.
OriginalsprogEngelsk
TidsskriftClinical Immunology
Vol/bind146
Udgave nummer2
Sider (fra-til)120-130
ISSN1521-6616
DOI
StatusUdgivet - 2013

Fingeraftryk

HIV-1
Peptides
Viral Load
Hematology
Interleukin-2
Flow Cytometry
Placebos
Safety

Citer dette

Karlsson, Ingrid ; Brandt, Lea ; Vinner, Lasse ; Kromann, Ingrid ; Andreasen, Lars Vibe ; Andersen, Peter ; Gerstoft, Jan ; Kronborg, Gitte ; Fomsgaard, Anders. / Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection. I: Clinical Immunology. 2013 ; Bind 146, Nr. 2. s. 120-130.
@article{ace920f78231455bb85ea8d7ea593915,
title = "Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection",
abstract = "We investigated the potential of inducing additional T-cell immunity during chronic HIV-1 infection directed to subdominant HIV-1 epitopes from common HLA-supertypes. Ten treatment-na{\"i}ve HIV-1-infected individuals were immunized with peptides in the adjuvant CAF01. One individual received placebo. T-cell immunogenicity was examined longitudinally by a flow cytometry (CD107a, IFNγ, TNFα, IL-2 and/or MIP1β expression) as well as IFNγ ELISPOT. Safety was evaluated by clinical follow up combined with monitoring of biochemistry, hematology, CD4 T-cell counts and viral load. New CD4 and CD8 T-cell responses specific for one or more vaccine epitopes were induced in 10/10 vaccinees. The responses were dominated by CD107a and MIP1β expression. There were no significant changes in HIV-1 viral load or CD4 T-cell counts. Our study demonstrates that the peptide/CAF01 vaccine is safe and that it is possible to generate new HIV-1 T-cell responses to defined epitopes in treatment-na{\"i}ve HIV-1-infected individuals.",
keywords = "Adjuvants, Immunologic, Adolescent, Adult, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Epitopes, T-Lymphocyte, Female, HIV Infections, HLA-A Antigens, HLA-B Antigens, HLA-C Antigens, Humans, Immunodominant Epitopes, Male, Middle Aged, Peptides, Single-Blind Method, Young Adult",
author = "Ingrid Karlsson and Lea Brandt and Lasse Vinner and Ingrid Kromann and Andreasen, {Lars Vibe} and Peter Andersen and Jan Gerstoft and Gitte Kronborg and Anders Fomsgaard",
note = "Copyright {\circledC} 2012 Elsevier Inc. All rights reserved.",
year = "2013",
doi = "10.1016/j.clim.2012.12.005",
language = "English",
volume = "146",
pages = "120--130",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Heinemann",
number = "2",

}

Karlsson, I, Brandt, L, Vinner, L, Kromann, I, Andreasen, LV, Andersen, P, Gerstoft, J, Kronborg, G & Fomsgaard, A 2013, 'Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection', Clinical Immunology, bind 146, nr. 2, s. 120-130. https://doi.org/10.1016/j.clim.2012.12.005

Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection. / Karlsson, Ingrid; Brandt, Lea; Vinner, Lasse; Kromann, Ingrid; Andreasen, Lars Vibe; Andersen, Peter; Gerstoft, Jan; Kronborg, Gitte; Fomsgaard, Anders.

I: Clinical Immunology, Bind 146, Nr. 2, 2013, s. 120-130.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection

AU - Karlsson, Ingrid

AU - Brandt, Lea

AU - Vinner, Lasse

AU - Kromann, Ingrid

AU - Andreasen, Lars Vibe

AU - Andersen, Peter

AU - Gerstoft, Jan

AU - Kronborg, Gitte

AU - Fomsgaard, Anders

N1 - Copyright © 2012 Elsevier Inc. All rights reserved.

PY - 2013

Y1 - 2013

N2 - We investigated the potential of inducing additional T-cell immunity during chronic HIV-1 infection directed to subdominant HIV-1 epitopes from common HLA-supertypes. Ten treatment-naïve HIV-1-infected individuals were immunized with peptides in the adjuvant CAF01. One individual received placebo. T-cell immunogenicity was examined longitudinally by a flow cytometry (CD107a, IFNγ, TNFα, IL-2 and/or MIP1β expression) as well as IFNγ ELISPOT. Safety was evaluated by clinical follow up combined with monitoring of biochemistry, hematology, CD4 T-cell counts and viral load. New CD4 and CD8 T-cell responses specific for one or more vaccine epitopes were induced in 10/10 vaccinees. The responses were dominated by CD107a and MIP1β expression. There were no significant changes in HIV-1 viral load or CD4 T-cell counts. Our study demonstrates that the peptide/CAF01 vaccine is safe and that it is possible to generate new HIV-1 T-cell responses to defined epitopes in treatment-naïve HIV-1-infected individuals.

AB - We investigated the potential of inducing additional T-cell immunity during chronic HIV-1 infection directed to subdominant HIV-1 epitopes from common HLA-supertypes. Ten treatment-naïve HIV-1-infected individuals were immunized with peptides in the adjuvant CAF01. One individual received placebo. T-cell immunogenicity was examined longitudinally by a flow cytometry (CD107a, IFNγ, TNFα, IL-2 and/or MIP1β expression) as well as IFNγ ELISPOT. Safety was evaluated by clinical follow up combined with monitoring of biochemistry, hematology, CD4 T-cell counts and viral load. New CD4 and CD8 T-cell responses specific for one or more vaccine epitopes were induced in 10/10 vaccinees. The responses were dominated by CD107a and MIP1β expression. There were no significant changes in HIV-1 viral load or CD4 T-cell counts. Our study demonstrates that the peptide/CAF01 vaccine is safe and that it is possible to generate new HIV-1 T-cell responses to defined epitopes in treatment-naïve HIV-1-infected individuals.

KW - Adjuvants, Immunologic

KW - Adolescent

KW - Adult

KW - CD4-Positive T-Lymphocytes

KW - CD8-Positive T-Lymphocytes

KW - Epitopes, T-Lymphocyte

KW - Female

KW - HIV Infections

KW - HLA-A Antigens

KW - HLA-B Antigens

KW - HLA-C Antigens

KW - Humans

KW - Immunodominant Epitopes

KW - Male

KW - Middle Aged

KW - Peptides

KW - Single-Blind Method

KW - Young Adult

U2 - 10.1016/j.clim.2012.12.005

DO - 10.1016/j.clim.2012.12.005

M3 - Journal article

C2 - 23314272

VL - 146

SP - 120

EP - 130

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -